The trial will test four drugs or drug combinations that are already approved to treat other illnesses. Ten countries have agreed to take part in the trial so far, and WHO Director-General Tedros Adhanom Ghebreyesus said he hopes other countries join.
The countries participating are Argentina, Bahrain, Canada, France, Iran, Norway, South Africa, Spain, Switzerland and Thailand.
The Solidarity trial will test whether any of the drugs reduce mortality rates, the time a patient is in the hospital and whether patients receiving the drugs need ventilation or intensive care units, according to STAT.
The drugs being tested are Gilead’s remdesivir; a combination of lopinavir and ritonavir, which are both HIV drugs made by AbbVie; a combination of lopinavir and ritonavir with interferon beta; and an antimalarial drug called chloroquine.
The last time the WHO launched a similar clinical trial was during the Ebola outbreak in 2018, STAT reported.
“Multiple small trials with different methodologies may not give us the clear strong evidence we need about which treatments help to save lives,” the WHO director-general said during a briefing in Geneva, according to STAT.
Read the full article here.
More articles on pharmacy:
CVS, Walgreens plan to test for COVID-19 in parking lots
6 things to know about the leading drug being tested to treat COVID-19
USP panel sends revised compounding standards back for expert review
